TIMOPTIC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TIMOPTIC (TIMOPTIC).
Non-selective beta-adrenergic receptor antagonist (beta-blocker). Reduces intraocular pressure by decreasing aqueous humor production, likely via blockade of beta-2 receptors in the ciliary epithelium.
| Metabolism | Partially metabolized in the liver by CYP2D6; significant first-pass metabolism after systemic absorption. |
| Excretion | Renal elimination: ~20% unchanged; biliary/fecal elimination: ~80% as metabolites. |
| Half-life | Terminal elimination half-life is approximately 4-6 hours in healthy adults; prolonged in renal impairment. |
| Protein binding | ~60% bound to plasma proteins (mainly albumin). |
| Volume of Distribution | Approximately 1.5 L/kg; distributes widely into tissues. |
| Bioavailability | Ophthalmic: systemic bioavailability ~20-30% after topical administration due to nasolacrimal drainage. |
| Onset of Action | Ophthalmic: 0.5 hours for intraocular pressure reduction. |
| Duration of Action | Ophthalmic: 12-24 hours; typically dosed once or twice daily. |
One drop of 0.25% or 0.5% solution in the affected eye(s) twice daily.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dosage adjustment required; timolol is primarily metabolized in the liver and excreted renally as metabolites with minimal active drug. Caution in severe renal impairment (CrCl <30 mL/min) due to potential systemic accumulation. |
| Liver impairment | No specific Child-Pugh based recommendations; use with caution in severe hepatic impairment due to reduced metabolism. |
| Pediatric use | Instill one drop of 0.25% solution in the affected eye(s) twice daily. For children with inadequate response, may increase to 0.5% solution twice daily. |
| Geriatric use | Start with the lowest concentration (0.25%) and monitor for systemic effects; elderly may be more sensitive to bradycardia and hypotension. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TIMOPTIC (TIMOPTIC).
| Breastfeeding | Timolol is excreted into breast milk in small amounts. The M/P ratio is unknown. At ophthalmic doses, risk to infant is low; however, observe for signs of beta-blockade (bradycardia, hypotension, hypoglycemia). Use with caution, especially in preterm or low birth weight infants. |
| Teratogenic Risk | Timolol is an ophthalmic beta-blocker. Systemic absorption is low but possible. Animal studies show no teratogenicity; human data are limited. First trimester: Risk cannot be excluded; consider benefit vs risk. Second/third trimesters: Potential for fetal bradycardia, growth restriction, and hypoglycemia; use with caution. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Bronchial asthma or history of bronchial asthma","Severe COPD","Sinus bradycardia","Heart block greater than first degree","Cardiogenic shock","Overt cardiac failure","Hypersensitivity to any component of the product"]
| Precautions | ["May mask signs of hypoglycemia and thyrotoxicosis","Exacerbation of bronchospasm in patients with asthma or COPD","Bradycardia and heart block, especially in patients with pre-existing conduction abnormalities","Rebound hypertension after abrupt discontinuation in patients with coronary artery disease","Increased risk of anaphylactic reactions and resistance to epinephrine treatment","Systemic absorption can occur with ophthalmic use leading to systemic beta-blockade effects"] |
Loading safety data…
| Fetal Monitoring | Maternal: Heart rate, blood pressure, signs of bronchospasm. Fetal: Ultrasound for growth, fetal heart rate monitoring to detect bradycardia; consider non-stress test if concerns. |
| Fertility Effects | Animal studies indicate no significant impact on fertility. Human data are lacking; theoretical effect from systemic beta-blockade on reproductive function is unlikely at ophthalmic doses. |